Spotlight Innovation — Investor Presentation (December 2014)
12 slides from Spotlight Innovation's investor presentation, Dec 4, 2014
Slide 1: Celtic Biotech: Fighting Cancer with Nature's Tools
e®cELTIC BIOTECH Fighting Cancer with Nature’s Tools December 2014 SUBSIDIARY OF SPOTUGHT INNOVATION
Slide 2: Celtic Biotech Iowa
Celtic Biotech lowa * Celtic Biotech develops novel therapeutic products for the treatment of solid cancers and pain in humans * Derived from naturally specialized receptor-binding proteins, these products have the potential to: — increase survivability — improve the quality of life for cancer patie
Slide 3: Where We Are
Where We Are * Merger between Celtic Biotech LTD and Celtic Biotech lowa completed June 2014 * Celtic Biotech products in Phase 1 Human Clinical Trials in France — Prior study showed efficacy in clinical setting — Products show significant analgesic properties ¢ Preparing follow-on products eScetnic
Slide 4: Cancer Defined
Cancer Defined * Cancer is a group of diseases, caused by both external and internal actors, characterized by the uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death. * |n 1990, 500,000 in the U.S. die from cancer. In 2012, 550,000 died from canc
Slide 5: The Cancer Market
ee The Cancer Market * 1in3 people in the Industrialised West will contract a form of cancer in their lifetime * Current cancer medications have an average response rate of approximately 20% * The global anticancer market is worth $80 billion a year — Aging population of developed world will ensure
Slide 6: Biggest selling oncology products 2013
Biggest selfing oncology products 2013, Brand Company Rituxan Roche Avastin Roche Herceptin Roche Gleevec Novartis Reviimid Celgene ‘Alimta Eli Lilly Velcade 48l/Takeda erbitux — BMS/ ‘Merck Serono Gardasil Merck & Co, Zytiga 38) Xeloda Roche Tarceva Roche Afinitor Novartis Sprycel BMS Tasigna Novar
Slide 7: Our People
eee Our People Dr. Paul F. Reid President and Director Dr. Reid has 20 years experience in drug development & production, new drug development, clinical trial design, and experimental design. His collaborations with Harvard University Professor Zheng Hong Qin have led to several patent applications
Slide 8: Our Pipeline
Our Pipeline CROTOXIN ¢ A protein extracted from the venom of a tropical snake. Crotoxin has an inherent targeting component, like a Mab, that makes it selective for tumor cells. CARDIOTOXIN * Cardiotoxin (CD) is a peptide isolated from the venom of cobras. CD has been shown to inhibit metastasis, a
Slide 9: Publications
Publications ‘Acta Pharmacol Sin. 2014 Crotoxin induces apoptosis and autophagy in human lung carcnora cells n vitro via activation of the p3EMAPK signaling pathway. Han R, LiangH, Qin ZH, Liu CY. Evid Based Complement Alternat Med. 2014, Ameliorating Adriamycin-Induced Chrante Kidney Disease in Rat
Slide 10: Clinical Responses
Clinical Responses Reference Plataetal. Costaet al. Costaet al. Costaet al. Curaetal. TOTAL Product vactcsi0 vectcai0 vactc310 a 59 subjects Dose 0.3me/m2{0,009me/Ke) O.3mg it Dally 0.0025-0.023 mg/Kg dally O.1ameke, weekly 0.014 mek weekly 0.03-0.22 mg/m2 (0.0009-0.007me/Ke) dally Cancer types invo
Slide 11: Competitive Comparison
Competitive Comparison Comparison of Crotoxin to other MTT biotherapies ‘Agent Tumour type Use Outcome Overall (Target) Response Tarceva/ NscLe Mono 2months LE 8% Erlotinib Pancreatic + chemo 0.3 month LE (EGFR) Avastin/ Colorectal + chemo 5 month LE NR Bevacieumab NSCLC + chemo 2 month LE (1 PR} (V
Slide 12: Milestones
Milestones * Patent issued: Crotoxin Administration for Cancer Treatment and Pain Relief * Registered with FDA — National Drug Code issued: 48142 * Organized a contract filler to provide sterile fill services eScetnicaicr ECH
Spotlight Innovation — Investor Presentation (December 2014) on 6ix